Guide to combination therapy in psychiatry: with special emphasis on fluvoxamine
Gespeichert in:
Hauptverfasser: | , |
---|---|
Format: | Buch |
Sprache: | English |
Veröffentlicht: |
Hannover
Hannoversche Ärzte-Verl.-Union
2000
|
Schlagworte: | |
Online-Zugang: | Inhaltsverzeichnis |
Beschreibung: | Literaturverz. S. 61 - 67 |
Beschreibung: | VI, 67 S. graph. Darst. : 21 cm |
ISBN: | 3931373088 |
Internformat
MARC
LEADER | 00000nam a2200000 c 4500 | ||
---|---|---|---|
001 | BV013431651 | ||
003 | DE-604 | ||
005 | 20020116 | ||
007 | t | ||
008 | 001107s2000 gw d||| |||| 00||| eng d | ||
016 | 7 | |a 959435719 |2 DE-101 | |
020 | |a 3931373088 |9 3-931373-08-8 | ||
035 | |a (OCoLC)48958814 | ||
035 | |a (DE-599)BVBBV013431651 | ||
040 | |a DE-604 |b ger |e rakddb | ||
041 | 0 | |a eng | |
044 | |a gw |c DE | ||
049 | |a DE-29 | ||
084 | |a XI 5400 |0 (DE-625)153014:12905 |2 rvk | ||
100 | 1 | |a Jaquenoud Sirot, Eveline |e Verfasser |4 aut | |
245 | 1 | 0 | |a Guide to combination therapy in psychiatry |b with special emphasis on fluvoxamine |c Eveline Jaquenoud Sirot ; Daniele Zullino |
264 | 1 | |a Hannover |b Hannoversche Ärzte-Verl.-Union |c 2000 | |
300 | |a VI, 67 S. |b graph. Darst. : 21 cm | ||
336 | |b txt |2 rdacontent | ||
337 | |b n |2 rdamedia | ||
338 | |b nc |2 rdacarrier | ||
500 | |a Literaturverz. S. 61 - 67 | ||
650 | 4 | |a Drug Interactions | |
650 | 4 | |a Drug Therapy, Combination | |
650 | 4 | |a Fluvoxamine |x pharmacology | |
650 | 4 | |a Mental Disorders |x drug therapy | |
650 | 0 | 7 | |a Arzneimittelwechselwirkung |0 (DE-588)4003147-0 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Cytochrome |0 (DE-588)4148701-1 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Fluvoxamin |0 (DE-588)4140883-4 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Kombinationstherapie |0 (DE-588)4194534-7 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Psychopharmakon |0 (DE-588)4047729-0 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Biotransformation |0 (DE-588)4006908-4 |2 gnd |9 rswk-swf |
689 | 0 | 0 | |a Psychopharmakon |0 (DE-588)4047729-0 |D s |
689 | 0 | 1 | |a Kombinationstherapie |0 (DE-588)4194534-7 |D s |
689 | 0 | 2 | |a Arzneimittelwechselwirkung |0 (DE-588)4003147-0 |D s |
689 | 0 | |5 DE-604 | |
689 | 1 | 0 | |a Cytochrome |0 (DE-588)4148701-1 |D s |
689 | 1 | 1 | |a Biotransformation |0 (DE-588)4006908-4 |D s |
689 | 1 | |5 DE-604 | |
689 | 2 | 0 | |a Fluvoxamin |0 (DE-588)4140883-4 |D s |
689 | 2 | 1 | |a Psychopharmakon |0 (DE-588)4047729-0 |D s |
689 | 2 | 2 | |a Biotransformation |0 (DE-588)4006908-4 |D s |
689 | 2 | |5 DE-604 | |
700 | 1 | |a Zullino, Daniele |e Verfasser |4 aut | |
856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009167165&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
999 | |a oai:aleph.bib-bvb.de:BVB01-009167165 |
Datensatz im Suchindex
_version_ | 1804128222021943296 |
---|---|
adam_text | I
IV Guide To Combination Therapy
Content
Preface Ill
Part I: Drug Drug Interactions 1
1 Types of interactions 3
a Desirable pharmacodynamic interactions 3
b Undesirable pharmacodynamic interactions 3
c Desirable pharmacokinetic interactions 4
d Undesirable pharmacokinetic interactions 4
1.1 Pharmacodynamic interactions 5
1.2 Pharmacokinetic interactions: Absorption and excretion . .7
1.2.1 Absorption 7
1.2.2 Excretion 9
a Passive excretion 9
b Active re absorption and active secretion 9
c Changed elimination due to manipulation of urinary pH ... .10
d Biliary excretion 11
1.3 Pharmacokinetic interactions: Metabolism 11
1.3.1 Phase I metabolism 12
1.3.2 Phase II metabolism 12
2 Variability in drug metabolism 15
2.1 The natural variability in the capacity
of the eliminating organ 15
2.1.1 Kidneys 15
2.1.2 Liver 15
2.2 External factors influencing the elimination rate of drugs . .16
2.2.1 Enzyme inhibition 16
a Competitive inhibition 17
b Non competitive inhibition 18
c Time course of inhibition 18
2.2.2 Enzyme induction 18 ;
Time course of induction 18 i
2.2.3 Effect of inhibition and induction on plasma concentrations . .19 j
Content V
3 Cytochrome P450 21
3.1 Cytochrome P450 3A4 23
3.2 Cytochrome P450 2D6 24
3.3 Cytochrome P450 2C 26
3.4 Cytochrome P450 1A2 26
3.5 Genetic and environmental factors influencing CYP 450 .27
3.5.1 Genetic factors 27
3.5.2 Environmental factors 29
4 Ten statements on drug interactions 31
Part II: Focus on fluvoxamine 35
5 Fluvoxamine in combination with psychotropics 37
5.1 Tricyclic antidepressants and classical neuroleptics 37
5.1.1 Metabolism of TCA s and classical neuroleptics 37
a Neuroleptics 37
b Tricyclics 38
5.1.2 Influence of fluvoxamine 41
5.1.3 Influence of fluoxetine and paroxetine (and sertraline) 41
5.2 Other psychotropics 43
5.2.1 Other antidepressants 43
5.2.2 Other neuroleptics 46
5.2.3 Benzodiazepines and other hypnotics 48
5.3 Remaining psychotropics 50
6. Fluvoxamine in combination with non psychotropics . . 55
6.1 Analgesics 55
6.2 Beta blockers 56
6.3 Other cardiovascular drugs 57
6.4 Other drugs 58
! References 61
i
|
any_adam_object | 1 |
author | Jaquenoud Sirot, Eveline Zullino, Daniele |
author_facet | Jaquenoud Sirot, Eveline Zullino, Daniele |
author_role | aut aut |
author_sort | Jaquenoud Sirot, Eveline |
author_variant | s e j se sej d z dz |
building | Verbundindex |
bvnumber | BV013431651 |
classification_rvk | XI 5400 |
ctrlnum | (OCoLC)48958814 (DE-599)BVBBV013431651 |
discipline | Medizin |
format | Book |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02334nam a2200577 c 4500</leader><controlfield tag="001">BV013431651</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20020116 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">001107s2000 gw d||| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">959435719</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3931373088</subfield><subfield code="9">3-931373-08-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)48958814</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV013431651</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 5400</subfield><subfield code="0">(DE-625)153014:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jaquenoud Sirot, Eveline</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Guide to combination therapy in psychiatry</subfield><subfield code="b">with special emphasis on fluvoxamine</subfield><subfield code="c">Eveline Jaquenoud Sirot ; Daniele Zullino</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hannover</subfield><subfield code="b">Hannoversche Ärzte-Verl.-Union</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">VI, 67 S.</subfield><subfield code="b">graph. Darst. : 21 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturverz. S. 61 - 67</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Interactions</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Therapy, Combination</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fluvoxamine</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mental Disorders</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelwechselwirkung</subfield><subfield code="0">(DE-588)4003147-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytochrome</subfield><subfield code="0">(DE-588)4148701-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Fluvoxamin</subfield><subfield code="0">(DE-588)4140883-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kombinationstherapie</subfield><subfield code="0">(DE-588)4194534-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biotransformation</subfield><subfield code="0">(DE-588)4006908-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Kombinationstherapie</subfield><subfield code="0">(DE-588)4194534-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelwechselwirkung</subfield><subfield code="0">(DE-588)4003147-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Cytochrome</subfield><subfield code="0">(DE-588)4148701-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Biotransformation</subfield><subfield code="0">(DE-588)4006908-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Fluvoxamin</subfield><subfield code="0">(DE-588)4140883-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="2"><subfield code="a">Biotransformation</subfield><subfield code="0">(DE-588)4006908-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zullino, Daniele</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009167165&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-009167165</subfield></datafield></record></collection> |
id | DE-604.BV013431651 |
illustrated | Illustrated |
indexdate | 2024-07-09T18:45:48Z |
institution | BVB |
isbn | 3931373088 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-009167165 |
oclc_num | 48958814 |
open_access_boolean | |
owner | DE-29 |
owner_facet | DE-29 |
physical | VI, 67 S. graph. Darst. : 21 cm |
publishDate | 2000 |
publishDateSearch | 2000 |
publishDateSort | 2000 |
publisher | Hannoversche Ärzte-Verl.-Union |
record_format | marc |
spelling | Jaquenoud Sirot, Eveline Verfasser aut Guide to combination therapy in psychiatry with special emphasis on fluvoxamine Eveline Jaquenoud Sirot ; Daniele Zullino Hannover Hannoversche Ärzte-Verl.-Union 2000 VI, 67 S. graph. Darst. : 21 cm txt rdacontent n rdamedia nc rdacarrier Literaturverz. S. 61 - 67 Drug Interactions Drug Therapy, Combination Fluvoxamine pharmacology Mental Disorders drug therapy Arzneimittelwechselwirkung (DE-588)4003147-0 gnd rswk-swf Cytochrome (DE-588)4148701-1 gnd rswk-swf Fluvoxamin (DE-588)4140883-4 gnd rswk-swf Kombinationstherapie (DE-588)4194534-7 gnd rswk-swf Psychopharmakon (DE-588)4047729-0 gnd rswk-swf Biotransformation (DE-588)4006908-4 gnd rswk-swf Psychopharmakon (DE-588)4047729-0 s Kombinationstherapie (DE-588)4194534-7 s Arzneimittelwechselwirkung (DE-588)4003147-0 s DE-604 Cytochrome (DE-588)4148701-1 s Biotransformation (DE-588)4006908-4 s Fluvoxamin (DE-588)4140883-4 s Zullino, Daniele Verfasser aut HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009167165&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
spellingShingle | Jaquenoud Sirot, Eveline Zullino, Daniele Guide to combination therapy in psychiatry with special emphasis on fluvoxamine Drug Interactions Drug Therapy, Combination Fluvoxamine pharmacology Mental Disorders drug therapy Arzneimittelwechselwirkung (DE-588)4003147-0 gnd Cytochrome (DE-588)4148701-1 gnd Fluvoxamin (DE-588)4140883-4 gnd Kombinationstherapie (DE-588)4194534-7 gnd Psychopharmakon (DE-588)4047729-0 gnd Biotransformation (DE-588)4006908-4 gnd |
subject_GND | (DE-588)4003147-0 (DE-588)4148701-1 (DE-588)4140883-4 (DE-588)4194534-7 (DE-588)4047729-0 (DE-588)4006908-4 |
title | Guide to combination therapy in psychiatry with special emphasis on fluvoxamine |
title_auth | Guide to combination therapy in psychiatry with special emphasis on fluvoxamine |
title_exact_search | Guide to combination therapy in psychiatry with special emphasis on fluvoxamine |
title_full | Guide to combination therapy in psychiatry with special emphasis on fluvoxamine Eveline Jaquenoud Sirot ; Daniele Zullino |
title_fullStr | Guide to combination therapy in psychiatry with special emphasis on fluvoxamine Eveline Jaquenoud Sirot ; Daniele Zullino |
title_full_unstemmed | Guide to combination therapy in psychiatry with special emphasis on fluvoxamine Eveline Jaquenoud Sirot ; Daniele Zullino |
title_short | Guide to combination therapy in psychiatry |
title_sort | guide to combination therapy in psychiatry with special emphasis on fluvoxamine |
title_sub | with special emphasis on fluvoxamine |
topic | Drug Interactions Drug Therapy, Combination Fluvoxamine pharmacology Mental Disorders drug therapy Arzneimittelwechselwirkung (DE-588)4003147-0 gnd Cytochrome (DE-588)4148701-1 gnd Fluvoxamin (DE-588)4140883-4 gnd Kombinationstherapie (DE-588)4194534-7 gnd Psychopharmakon (DE-588)4047729-0 gnd Biotransformation (DE-588)4006908-4 gnd |
topic_facet | Drug Interactions Drug Therapy, Combination Fluvoxamine pharmacology Mental Disorders drug therapy Arzneimittelwechselwirkung Cytochrome Fluvoxamin Kombinationstherapie Psychopharmakon Biotransformation |
url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009167165&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
work_keys_str_mv | AT jaquenoudsiroteveline guidetocombinationtherapyinpsychiatrywithspecialemphasisonfluvoxamine AT zullinodaniele guidetocombinationtherapyinpsychiatrywithspecialemphasisonfluvoxamine |